Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas S Heitmann

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Cancers|February 4, 2021
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and PerspectivesJonas S Heitmann, Martin Pfluegler, Gundram Jung, et al.
Cancers|October 14, 2022
Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease OutcomeMaddalena Marconato, Yacine Maringer, Juliane S Walz, et al.
Viruses|October 28, 2023
Long-Term Follow-Up of COVID-19 Convalescents-Immune Response Associated with Reinfection Rate and SymptomsAnna Seller, Christopher Hackenbruch, Juliane S Walz, et al.
Cellular Immunology|February 5, 2020
Genetic loss of NFAT2 (NFATc1) impairs B cell development of B1 and B2 B cellsMelanie Märklin, Jonas S Heitmann, Joseph Kauer, et al.
Scientific Reports|September 23, 2022
Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemiaMaddalena Marconato, Joseph Kauer, Helmut R Salih, et al.
International Journal of Hematology|April 9, 2020
CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantationMelanie Märklin, Ilona Hagelstein, Clemens Hinterleitner, et al.
Scientific Reports|September 10, 2021
DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosisAnna Chashchina, Melanie Märklin, Clemens Hinterleitner, et al.
Pathology Oncology Research : POR|August 29, 2025
B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatmentJulia M Ott, Verena Gassenmaier, Michael Bitzer, et al.
Viruses|March 30, 2023
Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID SyndromeChristopher Hackenbruch, Yacine Maringer, Christian M Tegeler, et al.
Pharmaceutical Statistics|October 26, 2022
Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stageJannik Labrenz, Dominic Edelmann, Jonas S Heitmann, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Cancers|February 4, 2021
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and PerspectivesJonas S Heitmann, Martin Pfluegler, Gundram Jung, et al.
Cancers|October 14, 2022
Immunopeptidome Diversity in Chronic Lymphocytic Leukemia Identifies Patients with Favorable Disease OutcomeMaddalena Marconato, Yacine Maringer, Juliane S Walz, et al.
Viruses|October 28, 2023
Long-Term Follow-Up of COVID-19 Convalescents-Immune Response Associated with Reinfection Rate and SymptomsAnna Seller, Christopher Hackenbruch, Juliane S Walz, et al.
Cellular Immunology|February 5, 2020
Genetic loss of NFAT2 (NFATc1) impairs B cell development of B1 and B2 B cellsMelanie Märklin, Jonas S Heitmann, Joseph Kauer, et al.
Scientific Reports|September 23, 2022
Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemiaMaddalena Marconato, Joseph Kauer, Helmut R Salih, et al.
International Journal of Hematology|April 9, 2020
CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantationMelanie Märklin, Ilona Hagelstein, Clemens Hinterleitner, et al.
Scientific Reports|September 10, 2021
DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosisAnna Chashchina, Melanie Märklin, Clemens Hinterleitner, et al.
Pathology Oncology Research : POR|August 29, 2025
B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatmentJulia M Ott, Verena Gassenmaier, Michael Bitzer, et al.
Viruses|March 30, 2023
Elevated SARS-CoV-2-Specific Antibody Levels in Patients with Post-COVID SyndromeChristopher Hackenbruch, Yacine Maringer, Christian M Tegeler, et al.
Pharmaceutical Statistics|October 26, 2022
Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stageJannik Labrenz, Dominic Edelmann, Jonas S Heitmann, et al.
Pageof 7